Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

(2012) Giovanni Palladini et al.   JOURNAL OF CLINICAL ONCOLOGY

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

(2012) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of D-type cyclins in AL amyloidosis plasma cells

(2012) John Cho Lee et al.   JOURNAL OF CLINICAL PATHOLOGY

Prognosis and risk assessment in AL amyloidosis – state of the art

(2011) E. Kastritis et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

(2011) T. Bochtler et al.   BLOOD

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

(2011) S. O. Schonland et al.   BLOOD

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

(2011) L. Lopez-Corral et al.   CLINICAL CANCER RESEARCH

Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis

(2011) Ping Zhou et al.   Clinical Lymphoma Myeloma & Leukemia

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

(2010) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Gene selection in microarray survival studies under possibly non-proportional hazards

(2010) Daniela Dunkler et al.   BIOINFORMATICS

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

(2010) S. Kumar et al.   BLOOD

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

(2010) S. Dietrich et al.   BLOOD

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

(2010) Ulrike Klein et al.   CANCER

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

(2010) K. Neben et al.   HAEMATOLOGICA

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Induction of angiogenesis by normal and malignant plasma cells

(2009) D. Hose et al.   BLOOD

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis

(2009) A. H. Bryce et al.   HAEMATOLOGICA

Prognostic Significance of Copy-Number Alterations in Multiple Myeloma

(2009) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

(2008) T. Bochtler et al.   BLOOD

AL amyloidosis and progression to multiple myeloma with gain(1q)

(2008) James Hoffman et al.   BRITISH JOURNAL OF HAEMATOLOGY